Arzneimittelforschung 2012; 62(02): 63-74
DOI: 10.1055/s-0031-1295483
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Design, Synthesis and Evaluation of Novel Benzimidazoles, Benzothiazoles and Benzofurans Incorporating Pyrazole Moiety as Antiangiogenic Agents

S. M. Rida
1   Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt
,
A. M. Youssef
1   Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt
,
M. H. Badr
1   Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt
,
A. Malki
2   Department of Biochemistry, Faculty of Science, Alexandria University, Alexandria, Egypt
,
Z. A. Sherif
3   Department of Oncology, Georgetown University Medical Center, Washington DC, USA
,
A. S. Sultan
2   Department of Biochemistry, Faculty of Science, Alexandria University, Alexandria, Egypt
3   Department of Oncology, Georgetown University Medical Center, Washington DC, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 12. August 2011

accepted 07. November 2011

Publikationsdatum:
16. Februar 2012 (online)

Preview

Abstract

Novel benzimidazoles, benzothiazoles and benzofurans incorporating pyrazole moiety have been synthesized and screened for their antiangogenic activities, by testing their ability to inhibit human umbilical vein endothelial cell (HUVEC) proliferation, cord formation and migration in response to chemoattractant. 3 compounds 19, 23 and 26 showed antiangiogenic activities at non-cytotoxic concentrations. Compound 19 was the most active with chemotaxis activity data nearly comparable to that of the positive control, TNP-470. Compound 42 showed a significant cytotoxic effect on the tested cancer cell lines and less antiangiogenesis activity compared to compounds 19, 23 and 26. All the tested compounds, in contrary to TNP-470, interfered with the migratory function of HUVECs in response to vascular endothelial growth factor rather than the endothelial cells proliferation or cord formation. Moreover, a docked pose of compounds 19 and 26 was obtained bound to kinase insert domain receptor using Molecular Operating Environment module.